D-0557-2023 Class II Terminated
FDA drug recall D-0557-2023 was initiated by PD-Rx Pharmaceuticals, Inc. on Apr 6, 2023 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 352 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 10, 2023
- Initiation Date
- Apr 6, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 352 bottles
Product description
Montelukast Sodium USP, 10 mg, 30 count-bottles, Rx only, Intas Pharm, Limited Ahmedabad 380 054 India Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063-0762-30
Reason for recall
CGMP deviations.
Distribution pattern
Nationwide in the US.
Code information
Lots: L22C80, I22D93, K21C72 Exp. 11/30/23; A23A90, B23A09 Exp. 07/31/24; K22C33 Exp. 05/31/24; G22E88, G22F66, I22E27, C22B27, D22B94, E22C71 Exp. 02/28/24; I21E36 Exp. 09/30/23
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0557-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026